Kidney intertwined with vines representing cancer treatment choices.

Kidney Cancer Treatment: Is Surgery Always Necessary?

Author's portrait.
Elliot Brynn in Health & Wellness December 2025 • 4 min read.

"Exploring the latest research on sunitinib and nephrectomy in treating metastatic renal cell carcinoma."


For years, the standard approach to treating metastatic renal cell carcinoma (mRCC) often involved nephrectomy – surgical removal of the kidney – followed by systemic therapy like sunitinib. The rationale was that removing the primary tumor could improve outcomes. However, recent research is challenging this long-held belief, suggesting that sunitinib alone might be a viable, and in some cases preferable, option.

The CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) trial, published in the New England Journal of Medicine, directly compared sunitinib alone versus nephrectomy followed by sunitinib in patients with mRCC. The results have sparked considerable debate and prompted a re-evaluation of treatment strategies.

This article dives into the CARMENA trial's findings, explores the nuances of patient selection, and examines emerging approaches like deferred cytoreductive nephrectomy. We'll break down the complex research to help you understand the evolving landscape of kidney cancer treatment and what it might mean for you or a loved one.

CARMENA Trial: Sunitinib vs. Surgery Plus Sunitinib

Kidney intertwined with vines representing cancer treatment choices.

The CARMENA trial aimed to determine if sunitinib alone was non-inferior to nephrectomy followed by sunitinib. Non-inferiority, in this context, means that sunitinib alone wouldn't be significantly worse than the traditional approach.

The trial's initial conclusion, based on an interim analysis, was that sunitinib alone met the criteria for non-inferiority, as the confidence interval for the hazard ratio of death did not exceed 1.20, a pre-defined margin. This led the researchers to suggest sunitinib alone could be a reasonable option, especially considering the potential risks and recovery time associated with surgery.

  • Improved Quality of Life: Avoiding surgery can lead to a better quality of life for patients, reducing the burden of surgical complications and recovery.
  • Faster Treatment Initiation: Starting systemic therapy like sunitinib without delay allows for quicker control of the disease.
  • Reduced Surgical Risks: Nephrectomy is a major surgery with inherent risks, which can be avoided with sunitinib-alone approach.
However, some experts have raised concerns about the interpretation of the CARMENA trial, particularly regarding the early termination of the trial due to slow enrollment. This early termination raises the question of whether the confidence limits of the confidence interval should have aligned with the O'Brien-Fleming boundary, which would have indicated a less definitive result.

Deferred Cytoreductive Nephrectomy: A Middle Ground?

Recognizing the ongoing debate and the potential benefits of both approaches, some researchers are exploring a 'middle ground' strategy: deferred cytoreductive nephrectomy. This involves initiating systemic therapy first, and then, if the patient responds well and the disease is controlled, considering nephrectomy.

This approach allows for rapid control of systemic disease while reserving surgery for patients who are most likely to benefit. Studies suggest that deferred nephrectomy may be associated with longer survival in select patients.

Ultimately, the optimal treatment strategy for metastatic renal cell carcinoma depends on individual patient characteristics, disease burden, and response to therapy. The CARMENA trial and emerging strategies like deferred nephrectomy highlight the importance of personalized treatment plans and shared decision-making between patients and their healthcare teams. Further research is needed to refine patient selection criteria and optimize the sequencing of systemic therapy and surgery.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

1

What did the CARMENA trial investigate regarding kidney cancer treatment?

The CARMENA trial compared using sunitinib alone to nephrectomy followed by sunitinib in treating metastatic renal cell carcinoma. The trial wanted to see if sunitinib alone was not significantly worse than the traditional approach of surgery followed by sunitinib. The results suggested that sunitinib alone could be a reasonable option, particularly when considering the risks and recovery time associated with surgery. It's important to note that the trial was stopped early due to slow enrollment, leading to some debate about the strength of the conclusions.

2

What is deferred cytoreductive nephrectomy, and how does it fit into kidney cancer treatment strategies?

Deferred cytoreductive nephrectomy is a strategy where systemic therapy, like sunitinib, is started first. If the patient responds well and the disease is controlled, then nephrectomy is considered. This approach seeks a middle ground between immediate surgery and systemic therapy alone, aiming to maximize benefits while minimizing risks. The idea is to only perform surgery on patients who are likely to benefit from it after initial treatment with sunitinib.

3

What are the potential benefits of using sunitinib alone instead of surgery followed by sunitinib?

Using sunitinib alone can lead to several benefits: improved quality of life by avoiding surgery, faster treatment initiation allowing for quicker control of the disease, and reduced surgical risks associated with nephrectomy. These factors contribute to a less burdensome treatment experience for patients.

4

What is nephrectomy, and why has it been a standard part of kidney cancer treatment?

Nephrectomy is the surgical removal of the kidney. In the context of metastatic renal cell carcinoma, it has traditionally been used to remove the primary tumor, with the goal of improving outcomes when followed by systemic therapy like sunitinib. However, recent research, including the CARMENA trial, has questioned whether nephrectomy is always necessary, leading to a re-evaluation of treatment strategies. While nephrectomy can reduce tumor burden, it also carries surgical risks and recovery time.

5

Why have the CARMENA trial's findings caused debate in the field of kidney cancer treatment, and what are the implications?

The CARMENA trial's findings have sparked debate due to the early termination of the trial and concerns whether the confidence limits should have aligned with the O'Brien-Fleming boundary, potentially indicating a less definitive result. Despite these concerns, the trial has prompted a shift towards considering sunitinib alone as a viable option in certain cases of metastatic renal cell carcinoma, leading to more individualized treatment approaches. Further research is needed to fully understand the implications of these findings and refine patient selection criteria.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.